ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 34; no. 6; pp. 2201 - 2202
Main Authors Stippel, D.L, Arns, W, Pollok, M, Beckurts, K.T.E, Hesse, U.J, Hölscher, A.H
Format Journal Article Conference Proceeding
LanguageEnglish
Published New York, NY Elsevier Inc 01.09.2002
Elsevier Science
Subjects
Adrenal Cortex Hormones - therapeutic use
Antilymphocyte Serum - therapeutic use
Biological and medical sciences
Cause of Death
Drug Resistance
Follow-Up Studies
Graft Rejection - drug therapy
Graft Rejection - epidemiology
Graft Survival - physiology
Humans
Immunomodulators
Kidney Transplantation - immunology
Kidney Transplantation - mortality
Kidney Transplantation - physiology
Medical sciences
Muromonab-CD3 - therapeutic use
Pharmacology. Drug treatments
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the urinary system
Survival Analysis
Time Factors
Human
Corticosteroid
Treatment resistance
Prognosis
Antilymphocyte globulin
Indication
Treatment efficiency
Transplantation
Monoclonal antibody
Homotransplantation
Long term
Kidney
Prevention
Rejection
Muromonab-CD3
Treatment
Urinary system
Follow up study
Surgery
Immunotherapy
Clinical trial
Graft
Immunosuppressive agent
Comparative study
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0041-1345
1873-2623
DOI:10.1016/S0041-1345(02)03200-1